Oncomine Lung cfDNA Cancer Panel

The Oncomine Lung CFTNA Cancer Panel analyzes cell-free tumor DNA (CFTNA) from lung cancer samples. It is used to guide treatment decisions based on the tumor's genomic profile.

Also known asOncomine Lung Cftna Cancer Panel Oncomine Lung Cftna Cancer Panel

Available via

Home Collection, Lab Visit

Contains

1 parameters

Earliest reports in

25 Working Days

Test details

Oncomine Lung cfDNA Cancer Panel Test in Bengaluru Overview

What is Oncomine Lung cfTNA Cancer Panel test?

The Oncomine Lung cfTNA Cancer panel test is a highly sensitive, next-generation sequencing (NGS) assay used in research to detect molecular changes in lung cancer, including driver mutations and resistance mutations. It analyzes (11 GENES - ALK, BRAF, EGFR, ERBB2, KRAS, NRAS, MET, PIK3CA,

ROS1, MAP2K1, TP53). This "liquid biopsy" approach offers a non-invasive method to gain insights into tumor evolution and identify potential biomarkers for cancer research. 

Why consider Oncomine Lung cfTNA Cancer Panel test?

Oncomine Lung cfTNA Cancer Panel test analyzes cell-free DNA and RNA from a blood sample (a liquid biopsy), eliminating the need for an invasive tissue biopsy.  It screens for a wide range of genetic alterations, including: Single Nucleotide Variants (SNVs), Insertions and Deletions (Indels), Copy Number Variations (CNVs)  and Gene Fusions

Who should get tested for Oncomine Lung cfTNA Cancer Panel test?

Clinicians should recommend Oncomine Lung cfTNA Cancer Panel for

  • Patients with suspected or confirmed advanced NSCLC where tissue is unavailable, inadequate, or risky to biopsy, or when a faster, less invasive genomic assessment is needed.
  • Patients on targeted therapy who require resistance profiling at progression, or those needing serial molecular monitoring to track response and clonal dynamics.

More Information about Oncomine Lung cfTNA Cancer Panel test

NGS can be beneficial due to its high sensitivity and specificity, using low amounts of sample. Additionally, NGS can determine an increased number of alterations simultaneously from the same quantity of sample. Therefore, NGS has been applied with success in the identification of lung cancer-specific mutations in paraffin-embedded tissue samples, with a higher rate than standard PCR testing. In lung cancer diagnosis, NGS is employed mainly in evaluating the gene alteration in key genes involved in the development of lung cancer. These genes are ALK, BRAF, EGFR, ERBB2, KRAS, NRAS, MET, PIK3CA, ROS1, MAP2K1, TP53).

OTHER NAMES: Oncomine Lung cfTNA Research Assay, Oncomine Lung cfDNA/cfRNA Panel, Oncomine Lung Liquid Biopsy Panel, Cell-free nucleic acid lung cancer panel (NGS)

 

 

Preparations

No special preparations needed

Test included
Oncomine Lung cfDNA Cancer Panel includes 1 parameter

  • Oncomine Lung Cftna Cancer Panel

Test code

G575

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
Peripheral BloodOthers3 ML

Specimen stability information

Peripheral Blood

Specimen rejection criteria

Test run frequency

Every Day TIME - 08:00

Turn around time

25 Working Days

Performing locations

Department

  • Advanced Molecular Diagnostics R&d

CPT and Loinc codes

Oncomine Lung cfDNA Cancer Panel

35000